Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jerry Karabelas
AddedMar 31, 2024
UpdatedMay 1, 2026
Jerry Karabelas

Jerry Karabelas

Board Member, Human Genome Sciences

Jerry Karabelas's Career

Human Genome Sciences
Human Genome Sciences

Rockville, MD, US

Board Member· Board
Regenxbio
Regenxbio

Rockville, MD, US

Board Member· Board
Braeburn
Braeburn

Plymouth Meeting, PA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jerry Karabelas's Career

Human Genome Sciences
Human Genome Sciences
Acquired01992Rockville, MD, US
Board Member· Board

Leadership at Human Genome Sciences

Colin GoddardColin GoddardBoard Member
J. Craig VenterJ. Craig VenterFounder
Allan BaxterAllan BaxterBoard Member

Similar to Human Genome Sciences

GSKGSKLondon, Greater London, GBBiotech, Pharmaceuticalsest. 2000GSKLondon, Greater London, GB · est. 2000

GSK PLC: A British multinational firm innovating in pharmaceuticals, biotech, and health products.

Public · $25.5M69.4k
Gilead SciencesGilead SciencesFoster City, CA, USPharmaceuticals, Therapiesest. 1987Gilead SciencesFoster City, CA, US · est. 1987

Gilead Sciences: An American biopharmaceutical firm innovating therapies for critical diseases.

Public · $2B17k
GeneDx HoldingsGeneDx HoldingsStamford, CT, USGenetic Testingest. 2017GeneDx HoldingsStamford, CT, US · est. 2017

Connecticut-based GeneDx, a software company merging diagnostics and data science for personalized health insights.

Public · $941M919
Gene SciencesGene SciencesSan Diego, CA, USTherapeuticsest. 2016Gene SciencesSan Diego, CA, US · est. 2016

Gene Sciences, Inc.: A US-based biotech company specializing in DNA-targeted therapeutics.

Public · $8M6
Regenxbio
Regenxbio
Public$638.2M4012008Rockville, MD, US
Board Member· Board

Leadership at Regenxbio

Allan FoxAllan FoxBoard Member
Alexandra GlucksmannAlexandra GlucksmannBoard Member
Daniel TasséDaniel TasséBoard Member
George MigauskyGeorge MigauskyBoard Member
Daniel Abdun-NabiDaniel Abdun-NabiBoard Member
Ken MillsKen MillsCEO
Braeburn
Braeburn
Late Stage Private$133M302012Plymouth Meeting, PA, US
Board Member· Board

Leadership at Braeburn

Dennis H. LangerDennis H. LangerBoard Member
Mike DerkaczMike DerkaczCEO
Seth L. HarrisonSeth L. HarrisonBoard Member

Similar to Braeburn

Bridge TherapeuticsBridge TherapeuticsBirmingham, AL, USPharmaceuticalsest. 2016Bridge TherapeuticsBirmingham, AL, US · est. 2016

Bridge Therapeutics: A specialty pharma company focused on chronic pain and opioid addiction solutions.

Series A · $4M9
Therabron TherapeuticsTherabron TherapeuticsRockville, MD, USProprietary Drugsest. 2007Therabron TherapeuticsRockville, MD, US · est. 2007

Therabron Therapeutics Inc.: A biopharmaceutical firm creating proprietary drugs for specific conditions.

Public · $17.9M30
Tremeau PharmaceuticalsTremeau PharmaceuticalsConcord, MA, USPain Therapiesest. 2016Tremeau PharmaceuticalsConcord, MA, US · est. 2016

Massachusetts-based pharmaceutical company specializing in non-opioid pain therapies.

Private Equity · $115.2M11
Brii BiosciencesBrii BiosciencesDurham, NC, USMedicines, Therapeuticsest. 2018Brii BiosciencesDurham, NC, US · est. 2018

Brii Biosciences: A US-China biotech firm innovating disease treatments for global health.

Public · $415M125

Jerry Karabelas's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Jerry Karabelas

MikeMikeBoard Member · HTG Molecular DiagnosticsKasper LageKasper LageBoard Member · BiogenLarry GoldLarry GoldBoard Member · MicroPhageJose CoronasJose CoronasCo-Founder · Thermal GradientbelcarbelcarBoard Member · Pliant TherapeuticsRonald I DozoretzRonald I DozoretzBoard Member · Genomind